Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

NCT02658279 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02658279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
January 22, 2016
Completion date
January 31, 2027
Enrollment
27 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, recurrent malignant glioma